We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

78 hedge funds and large institutions have $23.9M invested in Galectin Therapeutics in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 18 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 3

22% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 18

18% more call options, than puts

Call options by funds: $436K | Put options by funds: $368K

10% more funds holding

Funds holding: 71 → 78 (+7)

1.21% more ownership

Funds ownership: 17.65% → 18.87% (+1.2%)

11% less capital invested

Capital invested by funds: $26.9M → $23.9M (-$2.96M)

Holders
78
Holders Change
+7
Holders Change %
+9.86%
% of All Funds
1.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
22
Reduced
18
Closed
3
Calls
$436K
Puts
$368K
Net Calls
+$68K
Net Calls Change
-$325K

Top Buyers

Rank Fund Capital Flow
1
GWM
Geneos Wealth Management
Colorado
+$1.18M
2
BlackRock
BlackRock
New York
+$249K
3
JP Morgan Chase
JP Morgan Chase
New York
+$215K
4
OSAM
O'Shaughnessy Asset Management
Connecticut
+$190K
5
Osaic Holdings
Osaic Holdings
Arizona
+$158K

Top Sellers

Rank Fund Capital Flow
1
DADC
D.A. Davidson & Co
Montana
-$227K
2
Two Sigma Investments
Two Sigma Investments
New York
-$161K
3
Neuberger Berman Group
Neuberger Berman Group
New York
-$146K
4
RJA
Raymond James & Associates
Florida
-$74K
5
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$72K
Name Holding Trade Value Shares
Change 		Change in
Stake
RhumbLine Advisers
26
RhumbLine Advisers
Massachusetts
$63K +$7.43K +2,830 +11%
Deutsche Bank
27
Deutsche Bank
Germany
$62K +$19.6K +7,474 +37%
New York State Common Retirement Fund
28
New York State Common Retirement Fund
New York
$54K – – –
California Public Employees Retirement System
29
California Public Employees Retirement System
California
$53K – – –
UBS Group
30
UBS Group
Switzerland
$53K +$54K +20,572 +687%
Goldman Sachs
31
Goldman Sachs
New York
$52K +$6.58K +2,507 +12%
Invesco
32
Invesco
Georgia
$52K +$61.5K +23,434 New
WS
33
Wedbush Securities
California
$46K +$7.87K +3,000 +17%
Citadel Advisors
34
Citadel Advisors
Florida
$43K +$50.7K +19,333 New
VOYA Investment Management
35
VOYA Investment Management
Georgia
$42K +$13.9K +5,309 +39%
Neuberger Berman Group
36
Neuberger Berman Group
New York
$41K -$146K -55,730 -75%
RJFSA
37
Raymond James Financial Services Advisors
Florida
$41K +$47.8K +18,229 New
LPL Financial
38
LPL Financial
California
$39K -$2.62K -1,000 -5%
TRCT
39
Tower Research Capital (TRC)
New York
$37K -$68.7K -26,191 -61%
CAN
40
Cetera Advisor Networks
California
$36K – – –
CF
41
Centaurus Financial
California
$35K – – –
VCM
42
Vivaldi Capital Management
Illinois
$35K – – –
Renaissance Technologies
43
Renaissance Technologies
New York
$35K +$41K +15,627 New
WANY
44
Wealthspire Advisors (New York)
New York
$31K – – –
PPA
45
Parametric Portfolio Associates
Washington
$29K -$821 -313 -2%
AllianceBernstein
46
AllianceBernstein
Tennessee
$28K -$4.2K -1,600 -11%
BCM
47
Brookstone Capital Management
Illinois
$28K – – –
SKK
48
Shepherd Kaplan Krochuk
Massachusetts
$28K +$1.51K +575 +5%
FI
49
FormulaFolio Investments
Michigan
$28K +$33.4K +12,710 New
Barclays
50
Barclays
United Kingdom
$27K -$13.8K -5,274 -31%
1
2
3 4

GALT Hedge Fund Activity: Q4 2020 in Review

78 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2020, worth a combined $23.9M — down 11% from $26.9M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new GALT positions and 3 closed out — a net gain of 8 holders — while 22 added to existing stakes and 18 trimmed.

The largest buyer was Geneos Wealth Management, adding an estimated $1.18M. The largest seller was D.A. Davidson & Co, cutting an estimated $227K.

  • 78 institutional investors held Galectin Therapeutics (GALT) as of Q4 2020, up from 71 in Q3 2020.
  • Funds reported $23.9M of Galectin Therapeutics stock for Q4 2020, down 11% quarter-over-quarter.
  • 11 funds opened new Galectin Therapeutics positions in Q4 2020 and 3 closed out, a net change of +8 holders.
  • The largest Galectin Therapeutics buyer in Q4 2020 was Geneos Wealth Management, an estimated $1.18M added.
  • The largest Galectin Therapeutics seller in Q4 2020 was D.A. Davidson & Co, an estimated $227K sold.

Based on aggregated 13F filings for Q4 2020.